ArriVent BioPharma, Inc. (AVBP) vs Avalo Therapeutics, Inc. (AVTX)
A side-by-side comparison of ArriVent BioPharma, Inc. and Avalo Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVBP
ArriVent BioPharma, Inc.
$15.42HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
AVTX
Avalo Therapeutics, Inc.
$13.37HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
Total return — AVBP vs AVTX
growth of $100 · dividends reinvested · last 3yAVBP +42.3% (+12.5%/yr)AVTX +228.8% (+48.7%/yr)AVTX compounded faster over this window
AVBP AVTX
AVBP vs AVTX: by the numbers
- •AVBP is the larger company ($718M vs $703M market cap).
- •Both run net losses; AVBP's is the smaller (0.00% vs -170055.93% net margin).
Metrics side by side
Valuation
| Metric | AVBP | AVTX |
|---|---|---|
| P/S ratio | N/A | 11913.41 |
| P/B ratio | 1.96 | 1.57 |
Profitability
| Metric | AVBP | AVTX |
|---|---|---|
| Gross margin | 0.00% | 100.00% |
| Operating margin | 0.00% | -123601.69% |
| Net margin | 0.00% | -170055.93% |
| ROE | -44.63% | -22.36% |
| ROIC | -47.96% | -19.45% |
Growth (annualized)
| Metric | AVBP | AVTX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -60.88% |
| Total return CAGR (5Y) | N/A | -70.04% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.